Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Gleevec (imatinib) Clear all
Completed Not applicable Interventional

Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients

NCT00386373
View directory record Official record
Conditions
Leukemia
Interventions
Imatinib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 28, 2026, 10:14 AM EDT
Terminated Not applicable Interventional Results available

Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients

NCT01169753
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Placebo, Armodafinil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

New Individualized Therapy Trial for Metastatic Colorectal Cancer

NCT00867334
View directory record Official record
Conditions
Colorectal Neoplasm, Colorectal Cancer
Interventions
Imatinib mesylate and panitumumab, Standard-of-care treatment with panitumumab
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 28, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Myelofibrosis

NCT00245128
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders
Interventions
imatinib mesylate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Sep 28, 2026, 10:14 AM EDT
Terminated Phase 3 Interventional Results available

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

NCT01650805
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
ponatinib, imatinib (Gleevec/ Glivec)
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Burbank, California • Los Angeles, California • Pleasant Hill, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2014 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

NCT00006475
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT00982488
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib, Imatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
17
States / cities
Anaheim, California • Loma Linda, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

NCT00402766
View directory record Official record
Conditions
Mesothelioma
Interventions
Cisplatin, Imatinib Mesylate, Pemetrexed, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 28, 2026, 10:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

NCT00506779
View directory record Official record
Conditions
Uterine Cancer
Interventions
Imatinib Mesylate, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors

NCT00390156
View directory record Official record
Conditions
Unspecified Adult Solid Tumor
Interventions
bevacizumab, cyclophosphamide, imatinib
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Imatinib in Systemic Sclerosis

NCT00506831
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Imatinib mesylate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Sep 28, 2026, 10:14 AM EDT
Recruiting Phase 2 Interventional

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

NCT01746836
View directory record Official record
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

NCT00049192
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions
oblimersen sodium, imatinib mesylate, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 28, 2026, 10:14 AM EDT
Active, not recruiting Phase 2 Interventional

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

NCT05143840
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Interventions
Single Agent Asciminib, Low TKI, Elective Free Treatment
Drug · Combination Product · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

NCT00363649
View directory record Official record
Conditions
Leukemia
Interventions
GM-K562 cell vaccine, Interferon alfa, Sargramostim
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Sep 28, 2026, 10:14 AM EDT
Terminated Phase 3 Interventional Results available

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

NCT05557942
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AV-101
Drug
Lead sponsor
Aerovate Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

NCT00477269
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib mesylate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Newark, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

NCT00025246
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
imatinib mesylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 28, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

NCT00038649
View directory record Official record
Conditions
Myelogenous Leukemia, Chronic, Chronic Phase
Interventions
Gleevec
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 28, 2026, 10:14 AM EDT
Terminated Phase 2 Interventional Results available

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

NCT01391611
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
Pazopanib
Drug
Lead sponsor
Kristen Ganjoo
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

NCT00424515
View directory record Official record
Conditions
Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas
Interventions
Imatinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
5
States / cities
Denver, Colorado • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 1 Interventional

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

NCT01735968
View directory record Official record
Conditions
3rd Line GIST
Interventions
ST571 + BYL719
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 28, 2026, 10:14 AM EDT
Recruiting No phase listed Observational

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

NCT00816114
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Chart Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

A Study of Nilotinib Versus Imatinib in GIST Patients

NCT00785785
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
Nilotinib (AMN107), imatinib (STI571)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
28
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Duarte, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 28, 2026, 10:14 AM EDT